Clinical Trial Update: PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 study of AZD8186, a PI3K-β inhibitor, in combination with docetaxel for patients with PTEN or PIK3CB-mutant advanced solid tumors, including advanced or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Prostate Cancer
• Triple-negative Breast Cancer
• Unresectable Solid Tumor

Drugs mentioned

• AZD8186 (PI3K-beta inhibitor)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-09-21